ES2361269T3 - Anticuerpos especificos de tgf beta 1. - Google Patents

Anticuerpos especificos de tgf beta 1. Download PDF

Info

Publication number
ES2361269T3
ES2361269T3 ES06750860T ES06750860T ES2361269T3 ES 2361269 T3 ES2361269 T3 ES 2361269T3 ES 06750860 T ES06750860 T ES 06750860T ES 06750860 T ES06750860 T ES 06750860T ES 2361269 T3 ES2361269 T3 ES 2361269T3
Authority
ES
Spain
Prior art keywords
antibody
binding
tgf
image12
tgf beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06750860T
Other languages
English (en)
Spanish (es)
Inventor
Julian Davies
Craig Duane Dickinson
Lihua Huang
Bryan Edward Jones
David Matthew Marquis
Scott William Rowlinson
Ying Tang
Peter Edward Vaillancourt
Jeffry Dean Watkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2361269T3 publication Critical patent/ES2361269T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
ES06750860T 2005-04-22 2006-04-20 Anticuerpos especificos de tgf beta 1. Expired - Lifetime ES2361269T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67408205P 2005-04-22 2005-04-22
US674082P 2005-04-22

Publications (1)

Publication Number Publication Date
ES2361269T3 true ES2361269T3 (es) 2011-06-15

Family

ID=37192643

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06750860T Expired - Lifetime ES2361269T3 (es) 2005-04-22 2006-04-20 Anticuerpos especificos de tgf beta 1.

Country Status (23)

Country Link
US (2) US7619069B2 (enExample)
EP (1) EP1874818B1 (enExample)
JP (1) JP5070200B2 (enExample)
KR (1) KR100978684B1 (enExample)
CN (1) CN101163719A (enExample)
AT (1) ATE505489T1 (enExample)
AU (1) AU2006240056B2 (enExample)
BR (1) BRPI0608376A8 (enExample)
CA (1) CA2607448C (enExample)
CY (1) CY1111518T1 (enExample)
DE (1) DE602006021292D1 (enExample)
DK (1) DK1874818T3 (enExample)
EA (1) EA016038B1 (enExample)
ES (1) ES2361269T3 (enExample)
HR (1) HRP20110334T1 (enExample)
IL (1) IL186775A (enExample)
NO (1) NO20076003L (enExample)
PL (1) PL1874818T3 (enExample)
PT (1) PT1874818E (enExample)
RS (1) RS51845B (enExample)
SI (1) SI1874818T1 (enExample)
UA (1) UA93201C2 (enExample)
WO (1) WO2006116002A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036460A2 (en) * 2008-09-29 2010-04-01 Centocor Ortho Biotech Inc. Anti-cd147 antibodies, methods, and uses
EP2364370B1 (en) * 2008-11-22 2014-09-03 Astute Medical, Inc. Methods for prognosis of acute renal failure
US8685932B2 (en) * 2008-12-16 2014-04-01 Option Pharmaceuticals, Llc Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases
WO2010081004A1 (en) 2009-01-09 2010-07-15 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
US9289513B2 (en) 2011-03-23 2016-03-22 Option Pharmaceuticals, Llc Targeted cytokine for treatment of musculoskeletal diseases
EP2714735B1 (en) * 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
BR112014009866A2 (pt) 2011-10-25 2018-09-04 Onclave Therapeutics Limited formulações de anticorpos e métodos
WO2013134365A1 (en) 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
WO2013134665A1 (en) 2012-03-08 2013-09-12 Selig Sealing Products, Inc. Container sealing member with protected security component and removal tab
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
WO2015124297A1 (en) * 2014-02-19 2015-08-27 Merck Patent Gmbh Cancer-targeted il-12 immunotherapy
SG11201705721WA (en) 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh) * 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
RU2018131123A (ru) 2016-02-17 2020-03-17 Новартис Аг Антитела к tgf-бета2
WO2017143451A1 (en) * 2016-02-26 2017-08-31 Western University Anti-cd11d antibodies and uses thereof
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
CA3024465A1 (en) 2016-05-17 2017-11-23 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
CN109844124B (zh) * 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
WO2018043734A1 (en) * 2016-09-05 2018-03-08 Chugai Seiyaku Kabushiki Kaisha Anti-tgf-beta 1 antibodies and methods of use
EP3565839A4 (en) 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
WO2019045086A1 (ja) * 2017-08-29 2019-03-07 林化成株式会社 活性型もしくは潜在型ＴＧＦ−β１特異的抗体の用途
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
WO2019090263A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
JP2021529557A (ja) 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドＧｅｎｓｕｎ Ｂｉｏｐｈａｒｍａ， Ｉｎｃ． 抗腫瘍免疫チェックポイント調節因子アンタゴニスト
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
SG11202108099WA (en) 2019-01-30 2021-08-30 Scholar Rock Inc LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
EP3990116A1 (en) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
CA3166328A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
CA3167427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
TW202317185A (zh) * 2021-06-18 2023-05-01 美商健臻公司 抗ＴＧＦ－β抗體配製品及其用途
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
EP4599089A1 (en) 2022-10-05 2025-08-13 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
EP4676954A1 (en) 2023-03-07 2026-01-14 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
AU771635B2 (en) * 1999-01-05 2004-04-01 American National Red Cross, The Methods for treating conditions associated with the accumulation of excess extracellular matrix
US7763580B2 (en) * 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
JP2006525362A (ja) 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
WO2005010049A2 (en) * 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
JP2008501706A (ja) 2004-06-04 2008-01-24 ジェネンテック・インコーポレーテッド 疾患の治療方法
DK1931709T3 (en) * 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES

Also Published As

Publication number Publication date
UA93201C2 (ru) 2011-01-25
PL1874818T3 (pl) 2011-09-30
JP5070200B2 (ja) 2012-11-07
EA200702278A1 (ru) 2008-08-29
IL186775A0 (en) 2008-02-09
KR100978684B1 (ko) 2010-08-31
US20100040633A1 (en) 2010-02-18
CA2607448A1 (en) 2006-11-02
EP1874818A2 (en) 2008-01-09
CY1111518T1 (el) 2015-08-05
SI1874818T1 (sl) 2011-08-31
CN101163719A (zh) 2008-04-16
ATE505489T1 (de) 2011-04-15
WO2006116002A2 (en) 2006-11-02
EP1874818B1 (en) 2011-04-13
IL186775A (en) 2013-03-24
HRP20110334T1 (hr) 2011-06-30
US7619069B2 (en) 2009-11-17
WO2006116002A3 (en) 2007-02-01
EA016038B1 (ru) 2012-01-30
DE602006021292D1 (de) 2011-05-26
US8128927B2 (en) 2012-03-06
JP2008538564A (ja) 2008-10-30
KR20070114220A (ko) 2007-11-29
US20080050375A1 (en) 2008-02-28
BRPI0608376A2 (pt) 2010-11-16
RS51845B (sr) 2012-02-29
BRPI0608376A8 (pt) 2018-10-16
CA2607448C (en) 2014-11-18
AU2006240056A1 (en) 2006-11-02
WO2006116002A9 (en) 2007-07-19
DK1874818T3 (da) 2011-06-14
NO20076003L (no) 2008-01-22
AU2006240056B2 (en) 2012-02-16
PT1874818E (pt) 2011-05-05

Similar Documents

Publication Publication Date Title
CA2607448C (en) Tgf beta 1 specific antibodies
ES2633810T3 (es) Proteínas de unión a antígeno humanas que se unen a beta-Klotho, receptores de FGF y complejos de los mismos
ES3009462T3 (en) Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
ES2893148T3 (es) Anticuerpos contra el receptor alfa de la interleucina 4 canina
ES2713505T3 (es) Anticuerpos anti-TGF-beta modificados genéticamente y fragmentos de unión a antígeno
ES3036151T3 (en) Human cgrp receptor binding antibodies
ES2881642T3 (es) Anticuerpos anti-pro-miostatina/miostatina latente y usos de los mismos
ES2384176T3 (es) Anticuerpos anti-miostatina
JP2017031176A (ja) 脳疾患を治療するための抗タウｐＳ４２２抗体の使用
JP2010502633A (ja) 抗ミオスタチン抗体
ES2291626T3 (es) Anticuerpos humanos de ligando anti-hfas antagonista y fragmentos asociados.
ES2665851T3 (es) Nuevo anticuerpo anti-CTGF humano
JP2025523049A (ja) 抗Ｎｅｃｔｉｎ－４抗体及びその使用
CN114853890B (zh) 一种prlr抗原结合蛋白及其制备方法和应用
ES2566343T3 (es) Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos
CN113637070A (zh) 抗spike蛋白的抗体或抗原结合片段及其应用
US8207307B2 (en) Antibodies against human CCN1 and uses thereof
CN113637083A (zh) 用于治疗冠状病毒的融合蛋白及其应用
HK1119183A (en) Tgf beta 1 specific antibodies
HK40084128A (en) Coronavirus antibody and use thereof
BR122019020863B1 (pt) Ácido nucleico, vetor de expressão, microrganismo transgênico e método de produção de uma proteína de ligação a antígeno
PT103452A (pt) Polipéptidos que se ligam especificamente ao domínio ed-b de fibronectina com sequências especiais